Th-138: Phase II randomized trial of carboplatin + pemetrexed + bevacizumab, with or without atezolizumab, in patients with Stage IV nonsquamous nsclc who harbor a sensitizing EGFR mutation or have never smoked

Joseph Treat

Research output: Contribution to journal › Comment/debate

Fingerprint

Dive into the research topics of 'Th-138: Phase II randomized trial of carboplatin + pemetrexed + bevacizumab, with or without atezolizumab, in patients with Stage IV nonsquamous nsclc who harbor a sensitizing EGFR mutation or have never smoked'. Together they form a unique fingerprint.

Medicine and Dentistry